Following up on family members of patients with REM sleep behavior disorder
Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the First-degree Relatives of Patients With REM Sleep Behavior Disorder: a 7-year Prospective Study
This study is trying to see if family members of people with REM sleep behavior disorder show early signs of neurodegenerative diseases like Parkinson's.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 40 Years to 65 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin) |
| Trial ID | NCT05353959 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the progression of REM sleep behavior disorder (RBD) in first-degree relatives of patients diagnosed with idiopathic RBD. It aims to identify prodromal markers of neurodegeneration, particularly focusing on the familial aggregation of RBD and its correlation with Parkinson's disease. The study includes a cohort of 208 first-degree relatives of iRBD patients and 204 control relatives, assessing various neurodegenerative risk factors and symptoms. The goal is to enhance the understanding of how RBD may serve as an early indicator of neurodegenerative diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese individuals aged 40 or above who can provide informed consent and have a family history of REM sleep behavior disorder.
Not a fit: Patients younger than 40 or those unable to give informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and intervention for individuals at risk of developing Parkinson's disease.
How similar studies have performed: Other studies have shown promising results in identifying prodromal markers for neurodegenerative diseases, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chinese aged 40 or above * Can give informed consent for participation in the study * Sex- and age matched between groups Exclusion Criteria: * younger than 40 * not capable of giving informed consent for participation in the study
Where this trial is running
Shatin
- Shatin Hospital — Shatin, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Yun Kwok Wing, Prof — Chinese University of Hong Kong
- Study coordinator: Mandy Yu, MPH
- Email: mandyyu@cuhk.edu.hk
- Phone: 852-39197593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.